{"DataElement":{"publicId":"7245843","version":"1","preferredName":"Differentiated Thyroid Gland Carcinoma Stage Grouping CPTAC Stage","preferredDefinition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for differentiated thyroid carcinoma.","longName":"7245705v1.0:7245661v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7245705","version":"1","preferredName":"Differentiated Thyroid Gland Carcinoma Stage Grouping","preferredDefinition":"An adenocarcinoma arising from the thyroid gland showing extensive evidence of follicular cell differentiation.  According to the nuclear features of the malignant follicular cells, it is classified either as papillary, or follicular carcinoma._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","longName":"3461579v1.0:2230143v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"3461579","version":"1","preferredName":"Differentiated Thyroid Gland Carcinoma","preferredDefinition":"An adenocarcinoma arising from the thyroid gland showing extensive evidence of follicular cell differentiation.  According to the nuclear features of the malignant follicular cells, it is classified either as papillary, or follicular carcinoma. (NCI05)","longName":"C7153","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Differentiated Thyroid Gland Carcinoma","conceptCode":"C7153","definition":"An adenocarcinoma that arises from the thyroid gland and shows extensive evidence of follicular cell differentiation.  According to the nuclear features of the malignant follicular cells, it is classified either as papillary or follicular carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C02DD092-1787-CCAB-E040-BB89AD430207","latestVersionIndicator":"Yes","beginDate":"2012-05-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-16","modifiedBy":"ONEDATA","dateModified":"2012-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A33ED6BA-36CA-35D3-E053-F662850ADBAF","latestVersionIndicator":"Yes","beginDate":"2020-04-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-14","modifiedBy":"KNABLEJ","dateModified":"2020-05-12","changeDescription":"5/12/20 jk Released per Linda 4/30 email 4/14/20 jk created for THCA Baseline CRF unique staging question.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7245661","version":"1","preferredName":"CPTAC THCA Stage","preferredDefinition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics._A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and undifferentiated (anaplastic) carcinoma._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"7245661v1.0","context":"OCCPR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IVB55 and over","valueDescription":"Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8","ValueMeaning":{"publicId":"6572562","version":"1","preferredName":"Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8","longName":"6572562","preferredDefinition":"Stage IVB includes: 55 years and older: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8","conceptCode":"C140975","definition":"Stage IVB includes: 55 years and older: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BC112C2-326D-4042-E053-F662850A46CF","latestVersionIndicator":"Yes","beginDate":"2018-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-29","modifiedBy":"ONEDATA","dateModified":"2018-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A33ED6BA-3626-35D3-E053-F662850ADBAF","beginDate":"2020-04-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","deletedIndicator":"No"},{"value":"IVA55 and over","valueDescription":"Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8","ValueMeaning":{"publicId":"6572564","version":"1","preferredName":"Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8","longName":"6572564","preferredDefinition":"Stage IVA includes: 55 years and older: T4b, Any N, M0. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8","conceptCode":"C140974","definition":"Stage IVA includes: 55 years and older: T4b, Any N, M0. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BC112C2-3293-4042-E053-F662850A46CF","latestVersionIndicator":"Yes","beginDate":"2018-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-29","modifiedBy":"ONEDATA","dateModified":"2018-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A33ED6BA-363A-35D3-E053-F662850ADBAF","beginDate":"2020-04-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","deletedIndicator":"No"},{"value":"III55 and over","valueDescription":"Stage III Differentiated Thyroid Gland Carcinoma AJCC v8","ValueMeaning":{"publicId":"6572566","version":"1","preferredName":"Stage III Differentiated Thyroid Gland Carcinoma AJCC v8","longName":"6572566","preferredDefinition":"Stage III includes: 55 years and older: T4a, Any N, M0. T4a: Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage III Differentiated Thyroid Gland Carcinoma AJCC v8","conceptCode":"C140972","definition":"Stage III includes: 55 years and older: T4a, Any N, M0. T4a: Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BC112C2-32B9-4042-E053-F662850A46CF","latestVersionIndicator":"Yes","beginDate":"2018-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-29","modifiedBy":"ONEDATA","dateModified":"2018-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A33ED6BA-364E-35D3-E053-F662850ADBAF","beginDate":"2020-04-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","deletedIndicator":"No"},{"value":"II55 and over","valueDescription":"Stage II Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8","ValueMeaning":{"publicId":"6572568","version":"1","preferredName":"Stage II Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8","longName":"6572568","preferredDefinition":"Stage II includes: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8","conceptCode":"C140971","definition":"Stage II includes: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BC112C2-32DF-4042-E053-F662850A46CF","latestVersionIndicator":"Yes","beginDate":"2018-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-29","modifiedBy":"ONEDATA","dateModified":"2018-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A33ED6BA-3662-35D3-E053-F662850ADBAF","beginDate":"2020-04-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","deletedIndicator":"No"},{"value":"IIunder 55","valueDescription":"Stage II Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8","ValueMeaning":{"publicId":"6572555","version":"1","preferredName":"Stage II Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8","longName":"6572555","preferredDefinition":"Stage II includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8","conceptCode":"C140970","definition":"Stage II includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BD2D59A-CB86-2D24-E053-F662850ABDCD","latestVersionIndicator":"Yes","beginDate":"2018-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-29","modifiedBy":"ONEDATA","dateModified":"2018-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A33ED6BA-3676-35D3-E053-F662850ADBAF","beginDate":"2020-04-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","deletedIndicator":"No"},{"value":"I55 and over","valueDescription":"Stage I Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8","ValueMeaning":{"publicId":"6572570","version":"1","preferredName":"Stage I Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8","longName":"6572570","preferredDefinition":"Stage I includes: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8","conceptCode":"C140968","definition":"Stage I includes: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BC112C2-3305-4042-E053-F662850A46CF","latestVersionIndicator":"Yes","beginDate":"2018-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-29","modifiedBy":"ONEDATA","dateModified":"2018-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A33ED6BA-368A-35D3-E053-F662850ADBAF","beginDate":"2020-04-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","deletedIndicator":"No"},{"value":"I under 55","valueDescription":"Stage I Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8","ValueMeaning":{"publicId":"6572557","version":"1","preferredName":"Stage I Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8","longName":"6572557","preferredDefinition":"Stage I includes: Any T, Any N, M0. M0: No distant metastasis. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8","conceptCode":"C140967","definition":"Stage I includes: Any T, Any N, M0. M0: No distant metastasis. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BD2D59A-CBAC-2D24-E053-F662850ABDCD","latestVersionIndicator":"Yes","beginDate":"2018-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-29","modifiedBy":"ONEDATA","dateModified":"2018-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A33ED6BA-369E-35D3-E053-F662850ADBAF","beginDate":"2020-04-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7245660","version":"1","preferredName":"Clinical Proteomic Tumor Analysis Consortium Thyroid Gland Carcinoma Stage","preferredDefinition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.:A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and undifferentiated (anaplastic) carcinoma.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C157175:C4815:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Proteomic Tumor Analysis Consortium","conceptCode":"C157175","definition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Thyroid Gland Carcinoma","conceptCode":"C4815","definition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A33ED6BA-35F3-35D3-E053-F662850ADBAF","latestVersionIndicator":"Yes","beginDate":"2020-04-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A33ED6BA-3604-35D3-E053-F662850ADBAF","latestVersionIndicator":"Yes","beginDate":"2020-04-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-14","modifiedBy":"KNABLEJ","dateModified":"2020-05-12","changeDescription":"5/12/20 jk Released per Linda 4/30 email 4/14/20 jk created for CPTAC unique THCA stage question which includes all ages; PVs use AJCC terms/definitions for response values.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"10000439","version":"1","longName":"Thyroid","context":"OCCPR"},{"publicId":"6779571","version":"1","longName":"THCA Baseline","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Tumor Stage (Pathologic)","type":"Preferred Question Text","description":"Tumor Stage (Pathologic)","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3433F9F-7E83-7C32-E053-F662850AAE6B","latestVersionIndicator":"Yes","beginDate":"2020-04-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-14","modifiedBy":"KNABLEJ","dateModified":"2020-05-12","changeDescription":"5/12/20 jk Released per Linda 4/30 email 4/14/20 jk Created for CPTAC THCA Baseline CRF.  CPTAC question combines all possible ages, AJCC ed  8 THCA concepts used for response values.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}